Is Santhera Pharmaceuticals Holding AG (0QN1.L) a Buy, Sell, or Hold?
LSE : 0QN1.L
Santhera Pharmaceuticals Holding AG
$14.74935 CHF
-$0.26 (-1.72%)
- Volume
- 4.32K
- Average Volume
- 1.3K
- Market Capitalization
- $191.95M
- P/E Ratio
- -3.86
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $14.85
- Year Low
- $6.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.29
Company Overview
LSE
Dario Eklund
Medical - Pharmaceuticals
Healthcare
0QN1.L
78
CH
CHF
Liquidity Metrics
-8.27
1.29
0.89
0.36
0.00
Sales & Valuation
$77.18M
2.83
-16.71
-6.28
-2.60
Profitability
-$3.78
-$49.24M
-63.79%
-63.55%
684.83%
-33.25%
P/E Metrics
-3.86
0.13
0.13
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-5.91
2/9
$18.07M
$148.08M
$159.9M
-$58.34M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Sarah Holmes-Klotz | Global Head of People & Culture |
| Marc Claussen | Chief Commercial Officer |
| Oliver Kronenberg | Chief Legal Officer & Corporate Secretary |
| Shabir Hasham | Chief Medical Officer |
| Andreas Missy | Executive Vice President of Corporate Planning & Business Development |
| Catherine Ann Isted | Chief Financial Officer |
| Oliver Strub | Head of Compliance |
| Neville Kodkani | Head of Global Marketing & Partner Management |
| Dario Eklund | Chief Executive Officer |
| Marc Schrader | Chief Technology Officer |
| Geert Jan van Daal | Chief Commercial Officer |
| Thomas Meier | Founder & Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Santhera Pharmaceuticals Holding AG (LSE:0QN1.L) Stock
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland. ...
Frequently Asked Questions
-
What is the current Santhera Pharmaceuticals Holding AG (0QN1.L) stock price?
-
Santhera Pharmaceuticals Holding AG(LSE:0QN1.L) stock price is $14.74935 in the last trading session. During the trading session, 0QN1.L stock reached the peak price of $14.85 while $6.1461 was the lowest point it dropped to. The percentage change in 0QN1.L stock occurred in the recent session was --1.72% while the dollar amount for the price change in 0QN1.L stock was -$0.26.
-
0QN1.L's industry and sector of operation?
-
The LSE listed 0QN1.L is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of 0QN1.L?
-
Sarah Holmes-Klotz | Global Head of People & Culture
Marc Claussen | Chief Commercial Officer
Oliver Kronenberg | Chief Legal Officer & Corporate Secretary
Shabir Hasham | Chief Medical Officer
Andreas Missy | Executive Vice President of Corporate Planning & Business Development -
How many employees does 0QN1.L have?
-
Number of 0QN1.L employees currently stands at 78. 0QN1.L operates from Hohenrainstrasse 24, Pratteln, BL 4133, CH.
-
Link for 0QN1.L official website?
-
Official Website of 0QN1.L is: https://www.santhera.com
-
How do I contact 0QN1.L?
-
0QN1.L could be contacted at phone #41 61 906 89 50 and can also be accessed through its website. 0QN1.L operates from Hohenrainstrasse 24, Pratteln, BL 4133, CH.
-
How many shares of 0QN1.L are traded daily?
-
The average number of 0QN1.L shares traded daily for last 3 months was 1.3K.
-
What is the market cap of 0QN1.L currently?
-
The market value of 0QN1.L currently stands at $191.95M with its latest stock price at $14.74935